A115450 Stock Overview
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
HLB Therapeutics Co.,Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩12,420.00 |
| 52 Week High | ₩17,700.00 |
| 52 Week Low | ₩2,840.58 |
| Beta | 0.054 |
| 1 Month Change | 28.17% |
| 3 Month Change | 219.28% |
| 1 Year Change | 154.55% |
| 3 Year Change | 92.82% |
| 5 Year Change | 7.08% |
| Change since IPO | 5.17% |
Recent News & Updates
HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 38% Share Price Surge Not Quite Adding Up
Apr 11
There's Reason For Concern Over HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Massive 50% Price Jump
Feb 26Recent updates
HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) 38% Share Price Surge Not Quite Adding Up
Apr 11There's Reason For Concern Over HLB Therapeutics Co.,Ltd.'s (KOSDAQ:115450) Massive 50% Price Jump
Feb 26Does G-treeBNT (KOSDAQ:115450) Have A Healthy Balance Sheet?
Mar 19Did Business Growth Power G-treeBNT's (KOSDAQ:115450) Share Price Gain of 134%?
Dec 21
Shareholder Returns
| A115450 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -2.0% | -0.6% | -2.4% |
| 1Y | 154.5% | 2.4% | 1.9% |
Return vs Industry: A115450 exceeded the KR Biotechs industry which returned -3.5% over the past year.
Return vs Market: A115450 exceeded the KR Market which returned -1% over the past year.
Price Volatility
| A115450 volatility | |
|---|---|
| A115450 Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A115450's share price has been volatile over the past 3 months.
Volatility Over Time: A115450's weekly volatility has increased from 10% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 91 | n/a | hlbtherapeutics.co.kr |
HLB Therapeutics Co.,Ltd., a biotech company, develops pharmaceutical products in South Korea and internationally. It is developing GBT-201 using Thymosin beta for the treatment of ophthalmic diseases, such as dry eye syndrome and neurotrophic keratopathy; and OKN-007 for the treatment of glioblastoma brain tumor. It is also involved in the wholesale of vaccines, as well as manufactures electrical and electronic components, such as motors, pumps, and transformers.
HLB Therapeutics Co.,Ltd. Fundamentals Summary
| A115450 fundamental statistics | |
|---|---|
| Market cap | ₩932.07b |
| Earnings (TTM) | -₩1.99b |
| Revenue (TTM) | ₩53.75b |
17.3x
P/S Ratio-467.9x
P/E RatioIs A115450 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A115450 income statement (TTM) | |
|---|---|
| Revenue | ₩53.75b |
| Cost of Revenue | ₩46.46b |
| Gross Profit | ₩7.29b |
| Other Expenses | ₩9.28b |
| Earnings | -₩1.99b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -26.54 |
| Gross Margin | 13.56% |
| Net Profit Margin | -3.71% |
| Debt/Equity Ratio | 5.4% |
How did A115450 perform over the long term?
See historical performance and comparison